Gyre Therapeutics (GYRE) Research & Development (2010 - 2026)
Gyre Therapeutics (GYRE) reported Research & Development of $6.7 million for Q1 2026, up 117.71% year-over-year from $3.1 million in Q1 2025, and up 39.94% on a QoQ basis from $4.8 million in Q4 2025.
Gyre Therapeutics (GYRE) has 17 years of Research & Development data on file, last reported at $6.7 million in Q1 2026.
- Quarterly Research & Development rose 117.71% year-over-year to $6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.3 million (up 34.04% YoY) and the FY2025 annual result came in at $13.7 million, up 13.92% from the prior year.
- Research & Development improved to $6.7 million in Q1 2026 per GYRE's latest filing, from $4.8 million in the prior quarter.
- Across five years, Research & Development topped out at $9.7 million in Q1 2022 and bottomed at $803000.0 in Q3 2022.
- The 5-year median for Research & Development is $3.4 million (2024), against an average of $3.7 million.
- The widest annual swing landed in 2022, when Research & Development tumbled 96.05%; it then soared 274.72% in 2023.
- Tracing GYRE's Research & Development over 5 years: stood at $4.3 million in 2022, then climbed by 6.01% to $4.6 million in 2023, then declined by 18.74% to $3.7 million in 2024, then gained by 29.71% to $4.8 million in 2025, then soared by 39.94% to $6.7 million in 2026.
- Per Business Quant, the three latest GYRE Research & Development figures stand at $6.7 million (Q1 2026), $4.8 million (Q4 2025), and $2.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 6.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.74 Mn |
| Dec 31, 2025 | 4.82 Mn |
| Sep 30, 2025 | 2.36 Mn |
| Jun 30, 2025 | 3.43 Mn |
| Mar 31, 2025 | 3.10 Mn |
| Dec 31, 2024 | 3.71 Mn |
| Sep 30, 2024 | 2.78 Mn |
| Jun 30, 2024 | 3.36 Mn |
| Mar 31, 2024 | 2.18 Mn |
| Dec 31, 2023 | 4.57 Mn |
| Sep 30, 2023 | 3.01 Mn |
| Jun 30, 2023 | 3.57 Mn |
| Mar 31, 2023 | 2.64 Mn |
| Dec 31, 2022 | 4.31 Mn |
| Sep 30, 2022 | 803,000.00 |
| Jun 30, 2022 | 1.87 Mn |
| Mar 31, 2022 | 9.70 Mn |
| Dec 31, 2021 | -50.15 Mn |
| Sep 30, 2021 | 20.35 Mn |
| Jun 30, 2021 | 15.39 Mn |
| Mar 31, 2021 | 17.01 Mn |
| Dec 31, 2020 | -29.52 Mn |
| Sep 30, 2020 | 12.25 Mn |
| Jun 30, 2020 | 12.91 Mn |
| Mar 31, 2020 | 13.26 Mn |
| Dec 31, 2019 | 10.79 Mn |
| Sep 30, 2019 | 9.93 Mn |
| Jun 30, 2019 | 11.11 Mn |
| Mar 31, 2019 | 12.03 Mn |
| Dec 31, 2018 | 8.24 Mn |
| Sep 30, 2018 | 5.58 Mn |
| Jun 30, 2018 | 3.89 Mn |
| Mar 31, 2018 | 3.77 Mn |
| Dec 31, 2017 | 3.56 Mn |
| Sep 30, 2017 | 3.81 Mn |
| Jun 30, 2017 | 3.40 Mn |
| Mar 31, 2017 | 2.06 Mn |
| Dec 31, 2016 | 3.11 Mn |
| Sep 30, 2016 | 3.40 Mn |
| Jun 30, 2016 | 2.75 Mn |
| Mar 31, 2016 | 2.29 Mn |
| Dec 31, 2015 | 1.77 Mn |
| Sep 30, 2015 | 1.49 Mn |
| Jun 30, 2015 | 1.32 Mn |
| Mar 31, 2015 | 1.38 Mn |
| Dec 31, 2014 | 1.40 Mn |
| Sep 30, 2014 | 1.34 Mn |
| Jun 30, 2014 | 5.41 Mn |
| Mar 31, 2014 | 9.08 Mn |
| Dec 31, 2013 | -21.53 Mn |
| Sep 30, 2013 | 10.31 Mn |
| Jun 30, 2013 | 9.45 Mn |
| Mar 31, 2013 | 8.32 Mn |
| Dec 31, 2012 | 12.34 Mn |
| Sep 30, 2012 | 6.43 Mn |
| Jun 30, 2012 | 12.51 Mn |
| Mar 31, 2012 | 17.80 Mn |
| Dec 31, 2011 | 26.07 Mn |
| Sep 30, 2011 | 25.44 Mn |
| Jun 30, 2011 | 20.19 Mn |
| Mar 31, 2011 | 23.52 Mn |
| Dec 31, 2010 | 22.49 Mn |
| Sep 30, 2010 | 17.33 Mn |
| Jun 30, 2010 | 14.12 Mn |